CC – Cervical carcinoma
Introduction
In May 2022, the EMA granted pembrolizumab in combination with chemotherapy, and both with and without bevacicumab, marketing authorization for the treatment of persistent, recurrent, or metastatic cervical carcinoma (adenocarcinoma, squamous cell carcinoma, adeno-squamous cell carcinoma) in adults without prior therapy who have a PD-L1 expression of CPS ≥1. Accordingly, an immunohistological investigation will also be performed for this entity in the future with the aim of quantifying PD-L1 expression.
Data protection and the German Drug Advertising Act (HWG) require that the professional affiliation of the portal visitors. The complete page with all contents is only available to medical personnel.
You can login with DocCheck, you QuIP-Account or Access-Code.
Login with QuIP-Account
Please enter your user name (e-mail address) and the corresponding password, which you also need for your login to the ring trial portal www.quip.eu can be used.
Login with Access-Code
Please enter your personal code, which you have already received by voucher.